MA53351A - Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations - Google Patents
Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisationsInfo
- Publication number
- MA53351A MA53351A MA053351A MA53351A MA53351A MA 53351 A MA53351 A MA 53351A MA 053351 A MA053351 A MA 053351A MA 53351 A MA53351 A MA 53351A MA 53351 A MA53351 A MA 53351A
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaromatic
- modulators
- nmda receptors
- nmda
- receptors
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862714100P | 2018-08-03 | 2018-08-03 | |
PCT/US2019/044814 WO2020086136A2 (fr) | 2018-08-03 | 2019-08-02 | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53351A true MA53351A (fr) | 2022-01-12 |
MA53351B1 MA53351B1 (fr) | 2023-08-31 |
Family
ID=69228330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53351A MA53351B1 (fr) | 2018-08-03 | 2019-08-02 | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations |
Country Status (36)
Country | Link |
---|---|
US (3) | US10584131B2 (fr) |
EP (2) | EP4223760A1 (fr) |
JP (1) | JP7319369B2 (fr) |
KR (1) | KR20210039432A (fr) |
CN (1) | CN112513047B (fr) |
AR (1) | AR115905A1 (fr) |
AU (1) | AU2019368147A1 (fr) |
BR (1) | BR112021001967A2 (fr) |
CA (1) | CA3108519A1 (fr) |
CL (1) | CL2021000294A1 (fr) |
CO (1) | CO2021002898A2 (fr) |
CR (1) | CR20210125A (fr) |
CU (1) | CU24647B1 (fr) |
CY (1) | CY1126144T1 (fr) |
DK (1) | DK3830092T3 (fr) |
DO (1) | DOP2021000025A (fr) |
EA (1) | EA202190431A1 (fr) |
EC (1) | ECSP21014902A (fr) |
ES (1) | ES2951872T3 (fr) |
FI (1) | FI3830092T3 (fr) |
HR (1) | HRP20230774T1 (fr) |
HU (1) | HUE062566T2 (fr) |
IL (1) | IL280474B2 (fr) |
JO (1) | JOP20210020A1 (fr) |
LT (1) | LT3830092T (fr) |
MA (1) | MA53351B1 (fr) |
MX (1) | MX2021001367A (fr) |
PE (1) | PE20210948A1 (fr) |
PH (1) | PH12021550242A1 (fr) |
PL (1) | PL3830092T3 (fr) |
PT (1) | PT3830092T (fr) |
RS (1) | RS64359B1 (fr) |
SG (1) | SG11202101125VA (fr) |
SI (1) | SI3830092T1 (fr) |
WO (1) | WO2020086136A2 (fr) |
ZA (1) | ZA202101273B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3386591T (lt) * | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
EP3386990B1 (fr) | 2015-12-09 | 2023-04-19 | Novartis AG | Modulateurs des récepteurs nmda à base de thiénopyrimidinone et leurs utilisations |
EP3558318B1 (fr) | 2016-12-22 | 2023-12-20 | Novartis AG | Modulateurs des récepteurs nmda et utilisations de ceux-ci |
IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1067079A (fr) | 1976-07-22 | 1979-11-27 | Yamanouchi Pharmaceutical Co. | Composes heterobicycliques azotes |
FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
AU6643694A (en) | 1993-05-21 | 1994-12-20 | Pentapharm Ag | 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones |
CA2257950A1 (fr) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Promedicaments antagonistes de recepteurs de fibrinogenes |
US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
AU2001270149A1 (en) | 2000-06-26 | 2002-01-08 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
KR100880972B1 (ko) | 2004-07-13 | 2009-02-03 | 에프. 호프만-라 로슈 아게 | 설폰아마이드 유도체 |
TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
JP5256202B2 (ja) | 2006-09-11 | 2013-08-07 | エム・エス・ディー・オス・ベー・フェー | キナゾリノンおよびイソキノリノンアセトアミド誘導体 |
MX2009002685A (es) | 2006-09-11 | 2009-10-13 | Organon Nv | Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il). |
US7858782B2 (en) | 2006-12-15 | 2010-12-28 | Abraxis Bioscience, Llc | Triazine derivatives and their therapeutical applications |
EP1939187A1 (fr) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Dérivés de pyridopyrimidone hétéroaryle substitués |
AU2008214372A1 (en) | 2007-02-08 | 2008-08-14 | Merck Sharp & Dohme Corp. | Therapeutic agents |
EP2160389B1 (fr) | 2007-04-18 | 2014-03-12 | Probiodrug AG | Derivatives de thioxoquinazolinone en tant qu`inhibiteurs de la glutaminyl cyclase |
WO2008138126A1 (fr) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Dérivés bicycliques de pyrimidine en tant que bloqueurs des canaux calciques |
WO2009025784A1 (fr) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Composés hétérocycliques en tant qu'inhibiteurs de dipeptidylpeptidase-iv pour le traitement ou la prévention des diabètes |
TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
EA021938B1 (ru) | 2008-05-01 | 2015-10-30 | Сертрис Фармасьютикалз, Инк. | Хинолины и их аналоги в качестве модуляторов сиртуина |
MX2010012961A (es) | 2008-05-29 | 2011-03-03 | Sirtris Pharmaceuticals Inc Star | Imidazopiridina y analogos relacionados como moduladores de sirtuina. |
EP2138494A1 (fr) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Dérivés substitués d'alkyl pyrimidin-4-one |
CN104193740A (zh) | 2008-07-03 | 2014-12-10 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物 |
CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
ES2517690T3 (es) | 2008-09-29 | 2014-11-03 | Glaxosmithkline Llc | Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina |
DK2385938T3 (en) | 2009-01-12 | 2015-04-27 | Pfizer Ltd | Sulfonamidderivater |
WO2010111573A1 (fr) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Composés utilisés comme ligands des récepteurs cannabinoïdes |
EP2264035A1 (fr) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | B antagonistes de la glycine |
TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
MX2012004289A (es) | 2009-10-13 | 2012-06-12 | Msd Oss Bv | Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina. |
JP5871897B2 (ja) | 2010-03-26 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジルトリアゾール |
WO2011117381A1 (fr) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Inhibiteurs de kinase b-raf |
CA2805724A1 (fr) | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines et thiadiazolo[3,2-a]pyrimidines |
JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤 |
US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
TWI510480B (zh) | 2011-05-10 | 2015-12-01 | Gilead Sciences Inc | 充當離子通道調節劑之稠合雜環化合物 |
WO2013048928A1 (fr) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Composés pyrrolinone carboxamide utiles comme inhibiteurs de lipase endothéliale |
US8946430B2 (en) | 2011-09-30 | 2015-02-03 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
WO2013049104A1 (fr) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Pyridinedione carboxamides convenant comme inhibiteurs de la lipase endothéliale |
CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
PL2776038T3 (pl) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | Inhibitory acc i ich zastosowania |
MX354074B (es) | 2012-02-10 | 2018-02-12 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
US9278973B2 (en) | 2012-10-25 | 2016-03-08 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
WO2014139144A1 (fr) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Composés et compositions thérapeutiques |
WO2014179144A1 (fr) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Composés hétérocycliques fongicides |
SG11201600147TA (en) | 2013-06-28 | 2016-02-26 | Beigene Ltd | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
WO2015007453A1 (fr) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Dérivés hétérobicycliques microbiocides |
TW201609656A (zh) | 2013-09-26 | 2016-03-16 | 美涅莫辛製藥公司 | Nr2a之n-芳基甲基磺醯胺負向調節劑 |
LT3055315T (lt) | 2013-10-11 | 2018-10-25 | F. Hoffmann-La Roche Ag | Tiazolpirimidinonai kaip nmda receptorių aktyvumo moduliatoriai |
WO2015064714A1 (fr) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | Dérivé substitué en position 1 d'imidazopyrimidinone ayant une activité inhibitrice sur l'autotaxine |
CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
WO2016034703A1 (fr) | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Composés hétérocycliques ou carbocycliques condensés portant un radical cycloaliphatique substitué et leur utilisation pour traiter les maladies liées à la vasopressine |
US20170313719A1 (en) | 2014-11-18 | 2017-11-02 | Emory University | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto |
EP3283487B1 (fr) | 2015-04-15 | 2019-10-16 | H. Hoffnabb-La Roche Ag | Pyrimidopyrimidinones et leurs utilisation comme modulateurs du receptor nmda |
KR20180102052A (ko) | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
LT3386591T (lt) | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
EP3386990B1 (fr) | 2015-12-09 | 2023-04-19 | Novartis AG | Modulateurs des récepteurs nmda à base de thiénopyrimidinone et leurs utilisations |
US20170305861A1 (en) | 2016-04-25 | 2017-10-26 | Immunomet Therapeutics, Inc | Heteroaryl compounds comprising nitrogen and use thereof |
WO2018026371A1 (fr) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc |
EP3558318B1 (fr) | 2016-12-22 | 2023-12-20 | Novartis AG | Modulateurs des récepteurs nmda et utilisations de ceux-ci |
KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
-
2019
- 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
- 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
- 2019-08-02 EP EP23165151.4A patent/EP4223760A1/fr active Pending
- 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
- 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
- 2019-08-02 AR ARP190102209A patent/AR115905A1/es unknown
- 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
- 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
- 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
- 2019-08-02 CA CA3108519A patent/CA3108519A1/fr active Pending
- 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
- 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
- 2019-08-02 KR KR1020217006300A patent/KR20210039432A/ko active Search and Examination
- 2019-08-02 EP EP19876025.8A patent/EP3830092B1/fr active Active
- 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
- 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
- 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
- 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
- 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
- 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
- 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
- 2019-08-02 AU AU2019368147A patent/AU2019368147A1/en active Pending
- 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
- 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/fr active Application Filing
- 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
- 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
- 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
- 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
- 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
- 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
- 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
-
2021
- 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
- 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
- 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
- 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
- 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
- 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
- 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
-
2023
- 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA49971A (fr) | Vésicules extracellulaires modifiées et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA53351A (fr) | Modulateurs des récepteurs nmda hétéroaromatiques et leurs utilisations | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA50397A (fr) | Anticorps anti-tau et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA42665A (fr) | Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations | |
MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
MA55083A (fr) | Polyribonucléotides et leurs utilisations cosmétiques | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA53665A (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
MA49398A (fr) | Anticorps monoclonaux anti-igf-1r et utilisations de ceux-ci |